We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
신규 편입 · 포트폴리오 비중 0.01%
신규 편입 · 포트폴리오 비중 0.00%
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Consensus PT $51.5 · 6 analysts
Stored first · Google News · Yahoo Finance (English)
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid GuruFocus
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com - Investing.com India
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com Investing.com India
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com - Investing.com Canada
Form 144 Indivior Pharmaceuticals For: 10 July By Investing.com Investing.com Canada
INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value - Stock Titan
INDV (NASDAQ: INDV) files Form 144 reporting 18,586 shares and $764,628 value Stock Titan
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – DUS:E7P TradingView
Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable - MSN
Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable MSN
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 30. | After market close (AMC) | $0.92 | — | — | $306.55M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.38 | — | — | $266M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.3 | — | — | $889M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.3 | — | — | $583M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 01. 12. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 11. 01. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2025. 10. 31. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 28. | Craig-Hallum | — | Maintain | Buy → Buy | — | Craig-Hallum: Buy |
| 2025. 08. 06. | HC Wainwright & Co. | — | Initiate coverage | — → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 06. 30. | Craig-Hallum | — | Maintain | Buy → Buy | — | Craig-Hallum: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 175,767 | $5.36M | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 94,943 | $2.89M | 0.01% | — | New position |